Last reviewed · How we verify
NCT05077956: Sema4A MS
Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis
trial testing Cerebrospinal and Blood Serum Semaphorin 4A Levels in Relapsing Multiple Sclerosis. Withdrawn.
25 October 2023
Quick facts
| Lead sponsor | Providence Health & Services |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 19 October 2021 |
| Primary completion | 25 October 2023 |
| Estimated completion | 25 October 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cerebrospinal and Blood Serum Semaphorin 4A Levels
Conditions studied
- Relapsing Multiple Sclerosis — all drugs for Relapsing Multiple Sclerosis →
- Multiple Sclerosis — all drugs for Multiple Sclerosis →
Sponsor
Providence Health & Services — full company profile →
Who can join
Adults 18 to 55, female only, with Relapsing Multiple Sclerosis or Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Measure serum and cerebrospinal fluid Sema4A levels in female subjects with newly diagnosed and untreated relapsing multiple sclerosis, clinically stable relapsing multiple sclerosis receiving disease modifying therapy, relapsing multiple sclerosis receiving disease modifying therapy with breakthrough disease, or non-multiple sclerosis controls (patients without inflammatory central nervous system disease).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05077956
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Relapsing Multiple Sclerosis
Currently open trials in the same condition.
- NCT07161258 — A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescent · Phase 2 · recruiting
- NCT06846281 — Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Scle · Phase 3 · recruiting
- NCT07211633 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ub · Phase 3 · recruiting
- NCT07483450 — A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Rel · Phase 4 · recruiting
- NCT06847724 — Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Partici · Phase 3 · recruiting
Other Providence Health & Services trials
Trials by the same sponsor.
- NCT06175000 — Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Parti · Phase 2 · recruiting
- NCT04987996 — GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients · Phase 2 · withdrawn
- NCT05349890 — Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T) · Phase 1 · active not recruiting
- NCT04796584 — Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication · terminated
- NCT04417699 — SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05077956 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Providence Health & Services
- Last refreshed: 7 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05077956.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing